Table 4. Clearance of chemotherapeutic... | American Society of Hematology

Table 4.

Clearance of chemotherapeutic agents according to BMI category

		Population average systemic clearance, mL/min/m²
Drug and study	No. patients/no. courses	Underweight	Normal	At risk for overweight	Overweight	P*
High-dose methotrexate
All studies	450/3266	111.1	114.1	115.3	114.9	.47
Total XII	171/790	100.0	99.7	102.3	96.0	.77
Total XIIIB	230/2174	125.2	129.1	129.5	129.3	.55
Total XIV	49/302	92.5	98.8	99.8	95.5	.75
Etoposide						.41
Total XIIIB
D 29†	108/108	43.6	48.7	48.4	50.2
Wk 19†	27/27	38.6	43.2	42.9	44.5
Wk 54†	49/49	26.0	29.0	28.9	29.9
Cytarabine
Total XII	169/777	852.2	773.8	645.1	782.9	.56
Teniposide
Total XII	170/793	14.2	14.0	12.1	14.2	.35

		Population average systemic clearance, mL/min/m²
Drug and study	No. patients/no. courses	Underweight	Normal	At risk for overweight	Overweight	P*
High-dose methotrexate
All studies	450/3266	111.1	114.1	115.3	114.9	.47
Total XII	171/790	100.0	99.7	102.3	96.0	.77
Total XIIIB	230/2174	125.2	129.1	129.5	129.3	.55
Total XIV	49/302	92.5	98.8	99.8	95.5	.75
Etoposide						.41
Total XIIIB
D 29†	108/108	43.6	48.7	48.4	50.2
Wk 19†	27/27	38.6	43.2	42.9	44.5
Wk 54†	49/49	26.0	29.0	28.9	29.9
Cytarabine
Total XII	169/777	852.2	773.8	645.1	782.9	.56
Teniposide
Total XII	170/793	14.2	14.0	12.1	14.2	.35

P value reflects comparison to model with other significant covariates (eg, course, study, and age) included.

Day 29 of induction therapy, weeks 19 and 54 of continuation therapy.¹⁹